Autopsy report · NCT00748189
Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia
Cause of deathOther
“Majority of patients (62%) had been treated with next line therapies, including new highly effective therapies confounding the interpretation of the OS results.”
Life of this trial
- Registered 4 months before it started.
- Ran for about 9 years 5 months before it stopped.
- 447 participants enrolled.
- Results were posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Novartis Pharmaceuticals
- Sponsor type
- Industry
- Conditions
- Leukaemia, Lymphocytic, Chronic
- Interventions
- chlorambucil, tablets; ofatumumab (GSK1841157) infusion
- Participants
- 447
- Sites
- 154
- Countries
- Belgium, Brazil, Canada, Czechia, France, Germany, Greece, India, Ireland, Italy, Netherlands, Poland and more
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.